458 related articles for article (PubMed ID: 26611557)
21. Question 1: Co-trimoxazole dosing dilemma: what is the right dose?
Boast A; Osowicki J; Cole T; Curtis N; Gwee A
Arch Dis Child; 2015 Nov; 100(11):1089-93. PubMed ID: 26408788
[No Abstract] [Full Text] [Related]
22. Do patients on biologic drugs for rheumatic disease need PCP prophylaxis?
Tabanor JA; Lakshminarayanan S
Cleve Clin J Med; 2019 Jul; 86(7):449-453. PubMed ID: 31291178
[No Abstract] [Full Text] [Related]
23. Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Schmajuk G; Jafri K; Evans M; Shiboski S; Gianfrancesco M; Izadi Z; Patterson SL; Aggarwal I; Sarkar U; Dudley RA; Yazdany J
Semin Arthritis Rheum; 2019 Jun; 48(6):1087-1092. PubMed ID: 30449650
[TBL] [Abstract][Full Text] [Related]
24. Pneumocystis carinii pneumonia associated with methotrexate therapy in rheumatoid arthritis.
Flood DA; Chan CK; Pruzanski W
J Rheumatol; 1991 Aug; 18(8):1254-6. PubMed ID: 1941836
[TBL] [Abstract][Full Text] [Related]
25. Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections.
Clemente D; Cuadros EN; Lovillo MC; Hernández JC; Martín SG; Silveira LF; Cruz MJL; Tagarro A; Rueda RMA; López López A; Aritziturri MS; Calvo C
Eur J Pediatr; 2024 Feb; 183(2):915-927. PubMed ID: 38047962
[TBL] [Abstract][Full Text] [Related]
26. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
[TBL] [Abstract][Full Text] [Related]
27. Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India.
Shobha V; Chandrashekara S; Rao V; Desai A; Jois R; Dharmanand BG; Kumar S; Kumar P; Dharmapalaiah C; Mahendranath KM; Prasad S; Daware MA; Singh Y; Karjigi U; Nagaraj S; Anupama KR
Int J Rheum Dis; 2019 Feb; 22(2):280-287. PubMed ID: 30168281
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study.
Chan SCW; Chung HY; Lau CS; Li PH
Ann Clin Microbiol Antimicrob; 2021 Nov; 20(1):78. PubMed ID: 34763703
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
[TBL] [Abstract][Full Text] [Related]
30. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection.
Hughes MA; Parisi M; Grossman S; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1423-6. PubMed ID: 16029802
[TBL] [Abstract][Full Text] [Related]
31. [Pneumocystis pneumonia among patients with systemic diseases].
Khellaf M; Godeau B
Presse Med; 2009 Feb; 38(2):251-9. PubMed ID: 19062243
[TBL] [Abstract][Full Text] [Related]
32. Pneumocystis jirovecii pneumonia in systemic autoimmune rheumatic disease: A case-control study.
Tadros S; Teichtahl AJ; Ciciriello S; Wicks IP
Semin Arthritis Rheum; 2017 Jun; 46(6):804-809. PubMed ID: 27814896
[TBL] [Abstract][Full Text] [Related]
33. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.
Yale SH; Limper AH
Mayo Clin Proc; 1996 Jan; 71(1):5-13. PubMed ID: 8538233
[TBL] [Abstract][Full Text] [Related]
34. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor.
Winthrop KL
Nat Clin Pract Rheumatol; 2006 Nov; 2(11):602-10. PubMed ID: 17075599
[TBL] [Abstract][Full Text] [Related]
35. Pneumocystis jirovecii colonization in patients treated with infliximab.
Wissmann G; Morilla R; Martín-Garrido I; Friaza V; Respaldiza N; Povedano J; Praena-Fernández JM; Montes-Cano MA; Medrano FJ; Goldani LZ; de la Horra C; Varela JM; Calderón EJ
Eur J Clin Invest; 2011 Mar; 41(3):343-8. PubMed ID: 21299548
[TBL] [Abstract][Full Text] [Related]
36. Late onset tuberculosis infection in patients receiving anti-TNFα therapy.
Mongey AB; Doran JP; Kleinerova J; Fitzgerald O; McDonnell TJ
QJM; 2014 Jan; 107(1):69-71. PubMed ID: 23970181
[No Abstract] [Full Text] [Related]
37. Opportunistic infections in patients with temporal arteritis treated with corticosteroids.
Hedderwick SA; Bonilla HF; Bradley SF; Kauffman CA
J Am Geriatr Soc; 1997 Mar; 45(3):334-7. PubMed ID: 9063280
[No Abstract] [Full Text] [Related]
38. Herpes zoster in Crohn's disease during treatment with infliximab.
Wang X; Zhao J; Zhu S; Xia B
Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):237-9. PubMed ID: 24216569
[TBL] [Abstract][Full Text] [Related]
39. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
40. Pneumocystis pneumonia: an opportunistic infection occurring in patients with severe alcoholic hepatitis.
Faria LC; Ichai P; Saliba F; Benhamida S; Antoun F; Castaing D; Samuel D
Eur J Gastroenterol Hepatol; 2008 Jan; 20(1):26-8. PubMed ID: 18090986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
